Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Cinqair | reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Cinqair | Reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Withdrawn | |||
Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Do not list | Complete | ||
Ciprodex | Ciprofloxacin hydrochloride and dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | Do not list | Complete | ||
Ciprodex | Ciprofloxacin hydrochloride & dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | List with clinical criteria and/or conditions | Complete | ||
Clolar | clofarabine | Acute lymphoblastic leukemia | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Columvi | glofitamab | Relapsed or refractory diffuse large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Combigan Ophthalmic Solution | Brimonidine tartrate/timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | ||
COMPLERA | Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate | HIV infection | List | Complete | ||
Constella | Linaclotide | Irritable bowel syndrome with constipation | Do not list | Complete | ||
Contrave | naltrexone hydrochloride and bupropion hydrochloride | Chronic weight management in adults | Do not reimburse | Complete | ||
Copaxone | Glatiramer acetate | Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis | Do not list | Complete | ||
Cortiment | Budesonide | Ulcerative Colitis | Do not reimburse | Complete | ||
Corzyna | ranolazine | Stable angina pectoris, adults | Do not reimburse | Complete | ||
Cosentyx | Secukinumab | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Cosentyx | Secukinumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | ||
Cosentyx | secukinumab | Hidradenitis suppurativa | Active | |||
Cosentyx | Secukinumab | Plaque psoriasis | List with criteria/condition | Complete | ||
Cotellic | Cobimetinib | Metastatic melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Cresemba | isavuconazole | Treatment of invasive aspergillosis and mucormycosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Active | |||
Cubicin | Daptomycin | Skin and skin structure infections & bacteremia | Do not list | Complete | ||
Cuvposa | glycopyrrolate | chronic severe drooling, neurologic (pediatric) | Do not reimburse | Complete |